Clinical trial
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT02179086 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Lead sponsor
- NRG Oncology
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 4, 2014
- Completion date
- July 7, 2030
- Enrollment
- 624 (actual)
- Sites
- 237
Conditions
As the registry lists them; a condition with its own page is linked.